Project
A 24 week, randomized, double-blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in pulmonary arterial hypertension (PAH)
Aborted ยท 2012 until 2014
Burger Barbara, Haider Karin, Brutsche Martin
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Aborted
Start Date
2012
End Date
2014
Financing
Industry
Study Design
A 24 week, randomized, double-blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial
Keywords
TASIGNA, PAH